alemtuzumab MS
Selected indexed studies
- Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. (Mult Scler, 2020) [PMID:30785358]
- Management of MS-relapse during alemtuzumab therapy: Is it really B-cell-mediated? (Mult Scler Relat Disord, 2018) [PMID:29158120]
- Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy. (Neurol Neuroimmunol Neuroinflamm, 2020) [PMID:32769201]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. (2020) pubmed
- Management of MS-relapse during alemtuzumab therapy: Is it really B-cell-mediated? (2018) pubmed
- Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy. (2020) pubmed
- High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis. (2022) pubmed
- Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. (2019) pubmed
- Alemtuzumab: the advantages and challenges of a novel therapy in MS. (2014) pubmed
- [Alemtuzumab-induced Graves' disease]. (2023) pubmed
- Alemtuzumab and prescription medication use in the MS population. (2020) pubmed
- B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. (2021) pubmed
- Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series. (2024) pubmed